Skip to Main Content

Back to Press Releases
Dmitry Gabrilovich, M.D., Ph.D.

Function of Neutrophils During Tumor Progression Unraveled 

PHILADELPHIA — (Oct. 15, 2018) — Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and establishment of metastasis. Importantly, these neutrophils don’t possess the immunosuppressive characteristics of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). This seminal study was published online in Nature Immunology.

PMN-MDSCs are pathologically activated neutrophils with the ability to suppress immune responses to cancer and to promote tumor progression by conditioning tumor cells at the primary site. The role of neutrophils in setting the stage for metastatic growth at distant sites was not clear.

“Our research shed light on the role of neutrophils in the early stages of tumor progression, when overt metastasis has not yet formed but the conditions for metastatic spread are being created,” said Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and program leader of the Immunology, Microenvironment and Metastasis Program at Wistar. “Our study revealed that the activation of neutrophils in cancer is a two-phase process. We focused on the first phase and described the accumulation of a previously uncharacterized population of neutrophils that lack immunosuppressive activity but display a potent ability to spontaneously migrate, whereas the later phase is associated with accumulation of neutrophils with typical features of PMN-MDSCs.”

Gabrilovich and colleagues isolated neutrophils from the bone marrow of tumor bearing mice from different models of disease and at different stages of tumor development. The highly migratory population present in the early stages, which they designated as PMN-MDSC-like cells (PM-LCs), displays higher glucose uptake, increased metabolic activity and higher expression of genes associated with energy production. Further in vivo experiments demonstrated that PM-LCs promote seeding of tumor cells in distant sites and may favor metastatic dissemination.

The team validated the clinical relevance of these findings by describing the same spontaneous migratory behavior of neutrophils isolated from cancer patients.

“Our study elucidates the mechanism through which neutrophils contribute to early tumor dissemination,” said Jerome Mastio, Ph.D., postdoctoral fellow in the Gabrilovich Lab and co-first author of the study. “We describe the dynamic changes that neutrophils undergo in cancer, with PM-LCs representing the first step of pathologic activation.” 

This work was supported by National Institutes of Health grant P01 CA140043 and T32 CA09171. Core support for The Wistar Institute was provided by the Cancer Center Support Grant P30 CA010815.
 
Sima Patel and Shuyu Fu from The Wistar Institute are co-first authors on this study. Other co-authors from Wistar include George Dominguez, Abhilasha Purohit, Andrew Kossenkov, Cindy Lin, Kevin Alicea-Torres, Mohit Sehgal, Yulia Nefedova, Dario C. Altieri, and Zachary Schug. Other co-authors include Jie Zhou from Sun Yat-sen University, China; Lucia R. Languino from Thomas Jefferson University; Cynthia Clendenin and Robert H. Vonderheide from University of Pennsylvania; Charles Mulligan, Brian Nam, Neil Hockstein, Gregory Masters, and Michael Guarino from Helen F Graham Cancer Center at Christiana Care Health System.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer and infectious disease research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Print this Page

For press inquiries or more information please contact comm-marketing@wistar.org